ELECTROENCEPHALOGRAPHY KIT

Brand Owner Address Description
MUSE InteraXon Inc. 555 Richmond Street W, Suite 900 Toronto, Ontario M5H3E5 Canada Electroencephalography kit, for personal use, consisting of an electroencephalogram (EEG) headset, EEG sensing device, brain sensing headband, wearable headset device to measure, track, and monitor EEG brainwaves, and associated software sold as a unit therewith, all of the aforesaid in association with measurements and signals derived exclusively from the head, brain functioning, brain processes, brain activity and/or mental and cognitive measurements, analysis, functioning (including without limitation, eye movement, and/or galvanic skin response, and/or facial muscle tension) and training and not in any way associated with the field of cardiology;Data processing services, namely, processing and managing data produced by a wearable headset device that measures, tracks or monitors EEG brain waves, all of the aforesaid in association with measurements and signals derived exclusively from the head, brain functioning, brain processes, brain activity and/or mental and cognitive measurements, analysis, functioning (including without limitation, eye movement, and/or galvanic skin response, and/or facial muscle tension) and training and not in any way associated with the field of cardiology;
 

Where the owner name is not linked, that owner no longer owns the brand

    
Technical Examples
  1. A method and system for utilizing neurophysiologic information obtained by techniques such as quantitative electroencephalography (QEEG), electrode recordings, MRI in appropriately matching patients with therapeutic entities is disclosed. The present invention enables utilization of neurophysiologic information, notwithstanding its weak correlation with extant diagnostic schemes for mental disorders, for safer and expeditious treatment for mental disorders, discovering new applications for therapeutic entities, improved testing of candidate therapeutic entities, inferring the presence or absence of a desirable response to a treatment, and deducing the mode of action of one or more therapeutic entities. In particular, methods for effectively comparing neurophysiologic information relative to a reference set are disclosed along with database-based tools for deducing therapeutic entity actions on particular patients such that these tools are readily accessible to remote users.